Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function-Reference-Cited by-同舟云学术

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

Published:2015-06 Issue:6 Volume:65 Page:833-841
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Boertien Wendy E.,Meijer Esther,de Jong Paul E.,ter Horst Gert J.,Renken Remco J.,van der Jagt Eric J.,Kappert Peter,Ouyang John,Engels Gerwin E.,van Oeveren Willem,Struck Joachim,Czerwiec Frank S.,Oberdhan Dorothee,Krasa Holly B.,Gansevoort Ron T.

Funder

Otsuka Pharmaceutical Development and Commercialization Inc

Publisher

Elsevier BV

Subject

Nephrology

Reference23 articles.

1. Variation in age at ESRD in autosomal dominant polycystic kidney disease;Reed;Am J Kidney Dis,2008

2. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort;Boertien;Am J Kidney Dis,2013

3. Tolvaptan inhibits ERK-dependent cell proliferation, cl secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin;Reif;Am J Physiol Renal Physiol,2011

4. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat;Wang;J Am Soc Nephrol,2005

5. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease;Torres;Nat Med,2004

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in tubular biomarkers with dietary intervention and metformin in patients with autosomal dominant polycystic kidney disease: a post-hoc analysis of two clinical trials;BMC Nephrology;2024-06-25

2. Measured and Estimated Glomerular Filtration Rate to Evaluate Rapid Progression and Changes over Time in Autosomal Polycystic Kidney Disease: Potential Impact on Therapeutic Decision-Making;International Journal of Molecular Sciences;2024-05-05

3. Mechanistic complement of autosomal dominant polycystic kidney disease: the role of aquaporins;Journal of Molecular Medicine;2024-04-26

4. Influence of vasopressin receptor antagonists on triple‐whammy acute kidney injury: A VigiBase analysis;British Journal of Clinical Pharmacology;2023-12-04

5. Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers;Frontiers in Pediatrics;2023-11-10